Application value of recombinant human endostatin in the treatment of cardiac carcinoma
10.3760/cma.j.issn.1008-6706.2019.11.032
- VernacularTitle: 重组人血管内皮抑素在贲门癌治疗中的应用价值
- Author:
Hailong WANG
1
;
Qingguang ZHANG
Author Information
1. Department of Thoracic Surgery, the Affiliated Hospital of Binzhou Medical College, Binzhou, Shandong 256600, China
- Publication Type:Journal Article
- Keywords:
Endostatins;
Antineoplastic agents;
Stomach neoplasms;
Cardia;
Radiotherapy;
Drug therapy;
Antineoplastic combined chemotherapy protocols;
Review
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(11):1405-1408
- CountryChina
- Language:Chinese
-
Abstract:
Recombinant human endostatin is an antiangiogenic drug, which limits the progression of tumor through normalize the tumor vessels and inhibits the proliferation of tumor cells in combination with chemotherapeutic drugs; and directly inhibits the formation of neovascularization endothelium.Gastric cardia carcinoma is a common digestive tumor in China, which is mainly treated by surgical resection, radiotherapy and chemotherapy.Based on the principle of recombinant human vascular endostatin and its good effect in the treatment of various kinds of malignant tumors, especially in the radiochemotherapy of digestive tract malignant tumors.In order to inhibit the development of tumor, improve patients′ postoperative survival rate, and prolong the survival time of disease free progression, this article will discuss the application value of recombinant human vascular endostatin in the comprehensive therapy of cardiac carcinoma.
